Ohio Governor Mike DeWine announced on October 5, 2023, his intention to implement an emergency rule that would classify all synthetic kratom compounds as illegal drugs. This decisive move is aimed at addressing growing concerns over the safety and legality of synthetic versions of the herbal product, which is often marketed for its stimulant and sedative effects.
In his statement, DeWine emphasized the importance of swift action to protect public health. He called on the Ohio Board of Pharmacy to take immediate measures to classify these substances as illegal, citing evidence linking synthetic kratom to serious health risks. The governor’s initiative reflects a broader trend among states grappling with the implications of unregulated synthetic drugs.
Synthetic kratom, which is derived from the leaves of the Mitragyna speciosa tree, has garnered attention for its potential psychoactive effects. While traditional kratom has been used in various cultures for centuries, the synthetic variants can pose increased dangers due to the lack of regulation and quality control. DeWine’s proposal aims to mitigate these risks by prohibiting the sale and distribution of these compounds across the state.
The governor’s call for an emergency rule follows reports of adverse health effects associated with synthetic kratom use, including addiction and severe withdrawal symptoms. By designating these compounds as illegal, Ohio would join a growing list of states that have taken similar steps to regulate or ban synthetic drugs.
The Ohio Board of Pharmacy is expected to review the governor’s proposal in the coming days. If enacted, the emergency rule would provide law enforcement with additional tools to combat the distribution of synthetic kratom products. This move is seen as a necessary step to safeguard Ohio residents from the potential hazards of these unregulated substances.
As the state prepares to address this issue, advocates for public health are closely monitoring the situation. Many believe that regulatory measures are essential to ensure consumer safety and prevent the proliferation of dangerous synthetic drugs. The outcome of DeWine’s proposal could set a precedent for how states manage the challenges posed by emerging substances in the future.
